NF2 Tumor Suppressor Gene Inactivation in Advanced Papillary Renal Cell Carcinoma
Authors:
- 9 September 2020
- journal article
- letter
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 45 (5) , 716-718
Abstract
An abstract is unavailable. This article is available as a PDF only.Keywords
This publication has 8 references indexed in Scilit:
- Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC)American Journal of Surgical Pathology, 2020
- Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the KidneyCancer Discovery, 2016
- Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsetsNature Communications, 2016
- Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic ProfilingEuropean Urology, 2016
- Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic AlterationsEuropean Urology, 2016
- NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK InhibitionCancer Discovery, 2015
- Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomasNeuro-Oncology, 2012
- Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAKOncogene, 2006